Limits to Personalized Cancer Medicine.

@article{Tannock2016LimitsTP,
  title={Limits to Personalized Cancer Medicine.},
  author={I. Tannock and J. Hickman},
  journal={The New England journal of medicine},
  year={2016},
  volume={375 13},
  pages={
          1289-94
        }
}
The widespread dissemination of the idea of personalized oncology has spread faster than the underlying science. The authors argue that the principles of clinical investigation need to be applied to address the many unanswered questions. 
245 Citations
Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”
  • 4
  • PDF
Quantifying the Benefits of Genome-Driven Oncology.
  • 7
  • PDF
Precision Medicine: Progress, Pitfalls, and Promises
  • 3
  • PDF
Genomics and the History of Precision Oncology.
  • 3
The role of Next-Generation Sequencing in tumoral radiosensitivity prediction
  • 7
Barriers and Limitations
Precision oncology: as much expectations as limitations
  • 4
  • PDF
Precision oncology using a clinician‐directed, tailored approach to molecular profiling
  • 2
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 36 REFERENCES
Consensus on precision medicine for metastatic cancers: a report from the MAP conference.
  • C. Swanton, J. Soria, +16 authors F. André
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2016
  • 60
  • PDF
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
  • T. Yap, L. Yan, +15 authors A. Tolcher
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
  • 448
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
  • E. Amir, B. Šeruga, +4 authors A. Ocaña
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
  • 51
  • PDF
...
1
2
3
4
...